ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 9,470 shares, a growth of 66.4% from the October 15th total of 5,692 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily volume of 28,464 shares, the short-interest ratio is currently 0.3 days.
Institutional Investors Weigh In On ALPS Medical Breakthroughs ETF
Institutional investors have recently bought and sold shares of the business. NTV Asset Management LLC raised its holdings in ALPS Medical Breakthroughs ETF by 1.2% during the third quarter. NTV Asset Management LLC now owns 17,283 shares of the company’s stock valued at $1,008,000 after acquiring an additional 200 shares during the period. Harbor Investment Advisory LLC bought a new position in shares of ALPS Medical Breakthroughs ETF in the second quarter worth about $29,000. Steward Partners Investment Advisory LLC grew its position in shares of ALPS Medical Breakthroughs ETF by 9.3% during the third quarter. Steward Partners Investment Advisory LLC now owns 5,976 shares of the company’s stock worth $348,000 after purchasing an additional 508 shares in the last quarter. Kestra Advisory Services LLC grew its position in shares of ALPS Medical Breakthroughs ETF by 27.6% during the first quarter. Kestra Advisory Services LLC now owns 8,186 shares of the company’s stock worth $428,000 after purchasing an additional 1,772 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. grew its position in shares of ALPS Medical Breakthroughs ETF by 8.1% during the second quarter. Sterling Investment Advisors Ltd. now owns 23,800 shares of the company’s stock worth $1,539,000 after purchasing an additional 1,775 shares in the last quarter.
ALPS Medical Breakthroughs ETF Trading Down 0.6%
Shares of SBIO traded down $0.34 during trading hours on Tuesday, reaching $53.53. 24,873 shares of the stock traded hands, compared to its average volume of 37,120. ALPS Medical Breakthroughs ETF has a 52-week low of $45.65 and a 52-week high of $70.85. The company’s 50-day moving average price is $56.77 and its two-hundred day moving average price is $57.21. The company has a market cap of $179.33 million, a P/E ratio of 6.73 and a beta of 0.79.
About ALPS Medical Breakthroughs ETF
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.
Featured Articles
- Five stocks we like better than ALPS Medical Breakthroughs ETF
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.
